| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/22/2009 | CA2693015A1 Pleuromutilin derivatives and their use as antimicrobials |
| 01/22/2009 | CA2692862A1 Stable compositions |
| 01/22/2009 | CA2692768A1 Compositions for the treatment of metabolic disorders |
| 01/22/2009 | CA2692713A1 Heterocyclic modulators of pkb |
| 01/22/2009 | CA2692688A1 Process for producing a proanthocyanidin extract |
| 01/22/2009 | CA2692655A1 Synergistic combinations of vr-1 antagonists and cox-2 inhibitors |
| 01/22/2009 | CA2691995A1 Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound |
| 01/22/2009 | CA2690761A1 Benzimidazole poly(adp-ribose)polymerase inhibitors |
| 01/22/2009 | CA2690619A1 Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
| 01/22/2009 | CA2690110A1 Ampa receptor antagonists for neuropathic pain |
| 01/22/2009 | CA2690087A1 Ampa receptor antagonists and zonisamide for neuropathic pain |
| 01/22/2009 | CA2690086A1 Ampa receptor antagonists and aldose reductase inhibitors for neuropathic pain |
| 01/22/2009 | CA2688669A1 New combinations for the treatment of respiratory diseases |
| 01/21/2009 | EP2017355A1 Gene associated with arteriosclerotic disease, and use thereof |
| 01/21/2009 | EP2017337A1 Human tumor necrosis factor receptors |
| 01/21/2009 | EP2017331A1 Method of producing s-adenosyl-l-methionine-containing dry yeast having excellent storage stability, the product thereof and composition for oral intake |
| 01/21/2009 | EP2017289A1 Pharmaceutical composition for conformational disease |
| 01/21/2009 | EP2017281A1 Toll-like receptor 9 agonists |
| 01/21/2009 | EP2017279A1 Novel aminopyridine derivative having aurora-a-selective inhibitory activity |
| 01/21/2009 | EP2017278A1 Dihydropyrazolopyrimidinone derivative |
| 01/21/2009 | EP2017277A1 Thiophene-imidazopyridines |
| 01/21/2009 | EP2017275A1 Benzisoxazole compound |
| 01/21/2009 | EP2017269A2 A pharmaceutical compodition comprising form II crystalline Ritonavir and a preparation thereof |
| 01/21/2009 | EP2017266A1 Pyridazine derivatives and medicines containing the same as effective ingredients |
| 01/21/2009 | EP2017265A1 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| 01/21/2009 | EP2017263A1 Heteroarylamide lower carboxylic acid derivative |
| 01/21/2009 | EP2017262A1 Process for production of carotenoid |
| 01/21/2009 | EP2017261A1 Amine derivative having npy y5 receptor antagonist activity |
| 01/21/2009 | EP2017257A1 2-aminobutanol compound and use thereof for medical purposes |
| 01/21/2009 | EP2017251A1 Method for stabilization of reduced coenzyme q10 |
| 01/21/2009 | EP2016954A1 Antibodies against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and metabolites thereof |
| 01/21/2009 | EP2016947A1 Novel one step process for preparing cross-linked poly(allylamine) polymers |
| 01/21/2009 | EP2016946A1 Chitosan silicon dioxide coprecipitate composition for use as a therapeutically active agent |
| 01/21/2009 | EP2016945A1 Pharmaceutical containing thiazole derivative as active ingredient |
| 01/21/2009 | EP2016944A2 Angiogenesis inhibitor containing a derivative of rifampicin |
| 01/21/2009 | EP2016943A1 Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments |
| 01/21/2009 | EP2016942A1 Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders |
| 01/21/2009 | EP2016941A1 Transdermally absorbable donepezil preparation |
| 01/21/2009 | EP2016940A1 Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
| 01/21/2009 | EP2016939A1 Transdermally absorbable preparation comprising anti-dementia agent |
| 01/21/2009 | EP2016938A1 Preparation of submicron sized particles via dispersion and solevnt or liquid phase removal |
| 01/21/2009 | EP2016937A1 Formulation of liposomal vesicles in aqueous solutions with tear film characteristics |
| 01/21/2009 | EP2016936A1 Oil in water emulsion comprising NSAIDs and quaternary ammonium halides |
| 01/21/2009 | EP2016935A1 Pharmaceutical composition for topical application of poorly soluble compounds |
| 01/21/2009 | EP2016085A1 Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis |
| 01/21/2009 | EP2016082A2 Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno(2,3-d)pyrimidine |
| 01/21/2009 | EP2016081A1 Anti-viral pyrimidine nucleoside derivatives |
| 01/21/2009 | EP2016080A1 Dihydropyrazolopyrimidinone derivatives |
| 01/21/2009 | EP2016079A1 Polymorphs |
| 01/21/2009 | EP2016078A2 Pyrrolo- and thiazolo-pyridine compounds as hif modulators |
| 01/21/2009 | EP2016077A2 Pharmaceutical compounds |
| 01/21/2009 | EP2016076A2 Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof |
| 01/21/2009 | EP2016075A1 Thiazole derivatives and their use as anti-tumour agents |
| 01/21/2009 | EP2016074A1 Inhibitors of c-fms kinase |
| 01/21/2009 | EP2016073A1 Process for the preparation of pure irbesartan |
| 01/21/2009 | EP2016072A1 Factor xa inhibitors |
| 01/21/2009 | EP2016071A1 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 01/21/2009 | EP2016070A1 Inhibitors of c-fms kinase |
| 01/21/2009 | EP2016069A1 Bis-pyridinium compounds |
| 01/21/2009 | EP2016068A1 Pyrazole derivatives and their use as pi3k inhibitors |
| 01/21/2009 | EP2016065A2 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis |
| 01/21/2009 | EP2016063A1 Thiazole derivatives as inhibitors of p13 kinase |
| 01/21/2009 | EP2016062A2 Anti-viral agents that activate rnase l |
| 01/21/2009 | EP2016061A1 Compounds which potentiate ampa receptor and uses thereof in medicine |
| 01/21/2009 | EP2016058A1 Inhibitors of c-fms kinase |
| 01/21/2009 | EP2016057A1 C-fms kinase inhibitors |
| 01/21/2009 | EP2016055A1 Inhibitors of p38 map kinase |
| 01/21/2009 | EP2016052A1 Crystalline (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate |
| 01/21/2009 | EP2016051A2 Beta-crystalline form of perindopril arginine salt, method for making same, and pharmaceutical compositions containing same |
| 01/21/2009 | EP2016049A1 3- (aminomethyliden) 2-indolinone derivatives and their use as cell proliferation inhibitors |
| 01/21/2009 | EP2016048A1 A crystalline form b4 of atorvastatin magnesium and a process thereof |
| 01/21/2009 | EP2016047A1 Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1 |
| 01/21/2009 | EP2016044A2 Synthesis of tetracyclines and analogues thereof |
| 01/21/2009 | EP2016039A1 Terphenyl derivatives for treatment of alzheimer' s disease |
| 01/21/2009 | EP2015782A2 Compositions and methods for modulating gene expression |
| 01/21/2009 | EP2015759A2 Combination therapy |
| 01/21/2009 | EP2015758A2 Compounds and methods for modulating expression apob |
| 01/21/2009 | EP2015757A2 Hydrolytically-resistant boron-containing therapeutics and methods of use |
| 01/21/2009 | EP2015756A2 Methods for treating or preventing disorders using ecdysteroid compositions |
| 01/21/2009 | EP2015754A2 Uses of dpp-iv inhibitors |
| 01/21/2009 | EP2015753A2 Inhibition of hiv infection through chemoprophylaxis |
| 01/21/2009 | EP2015751A2 Salts of pyridazine compounds |
| 01/21/2009 | EP2015750A2 Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| 01/21/2009 | EP2015749A2 Methods for treating cognitive and other disorders |
| 01/21/2009 | EP2015748A2 Method of inhibiting c kit kinase |
| 01/21/2009 | EP2015747A2 Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases |
| 01/21/2009 | EP2015746A2 Use of substituted glycerin derivatives for producing a pharmaceutical preparation |
| 01/21/2009 | EP2015745A2 Macrocyclic kinase inhibitors |
| 01/21/2009 | EP2015744A2 Regulating fat and carbohydrate oxidation in muscle tissue comprising controlling carnitine content in muscle |
| 01/21/2009 | EP2015743A2 Glutadon |
| 01/21/2009 | EP2015742A2 Reducing risk of type 2 diabetes (t2d) |
| 01/21/2009 | EP2015741A2 Histone deacetylase inhibitors for the treatment of neurodegeneration |
| 01/21/2009 | EP2015740A1 Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof |
| 01/21/2009 | EP2015739A1 Novel pharmaceutical compositions for optimizing substitution treatments and extending the pharmacopoeia to global treatment of addictions |
| 01/21/2009 | EP2015738A1 Use of a dermatological composition comprising a combination of hydroquinone, fluocinolone acetonide and tretinoin, for treating hyperpigmentation of pathological scars |
| 01/21/2009 | EP2015735A1 Tolterodine beads |
| 01/21/2009 | EP2015731A2 Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic- analgesic drug and proton pump inhibitor |
| 01/21/2009 | EP2015729A2 Improved storage stable one component polyurethane system |
| 01/21/2009 | EP2015728A2 Liquid pharmaceutical formulation |
| 01/21/2009 | EP2015647A2 Iron complex for use in the treatment and/or prevention of nutritional disorders |